Last reviewed · How we verify
NCT04766294: COVID-19
Macrophage Activation Markers in COVID-19 Patients
trial in COVID-19 in 70 participants. Completed in 1 April 2021.
15 March 2021
Quick facts
| Lead sponsor | Sohag University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 25 April 2020 |
| Primary completion | 15 March 2021 |
| Estimated completion | 1 April 2021 |
| Sites | 1 location across Egypt |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Sohag University
Who can join
Adults 19 to 70, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aiming to find the relation between the severity of COVID-19 in diabetic and obese patients and the high serum levels of matrix metalloproteinase-7 (MMP-7),matrix metalloproteinase-9 (MMP-9), TGF-β and PDGF Macrophage Activation Markers
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of High Serum Levels of MMP-7, MMP-9, TGF-β and PDGF Macrophage Activation Markers on Severity of COVID-19 in Obese-Diabetic Patients.
Nasr El-Din A, Ata KAE, Abdel-Gawad AR, Fahmy NF. · · 2021 · cited 28× · PMID 34611417 · DOI 10.2147/idr.s329004
Verify or expand the search:
- PubMed search for NCT04766294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Sohag University trials
Trials by the same sponsor.
- NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
- NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
- NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
- NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04766294 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sohag University
- Last refreshed: 24 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04766294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing